Conference data: Positive phase III trial of once weekly exenatide for treatment of type 2 diabetes in adolescents aged 10–17

This double-blind RCT (n=83) met its primary endpoint, demonstrating that exenatide once weekly reduced HbA1c from baseline vs placebo at 24 weeks, with least squares (LS) mean changes of −0.36% and +0.49%, respectively and a between-group LS mean difference of −0.85% (P=0.012).

Source:

Biospace Inc.